Patents by Inventor Christopher Thomas Halsall

Christopher Thomas Halsall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinazoline derivatives as tyrosine kinase inhibitors
    Patent number: 8735410
    Abstract: The invention concerns quinazoline derivatives of the Formula I, or pharmaceutically acceptable salts thereof: wherein each of R1, R2, R3, R4 and m are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, and, for example, EGFR tyrosine kinase.
    Type: Grant
    Filed: February 24, 2006
    Date of Patent: May 27, 2014
    Assignee: AstraZeneca AB
    Inventors: Christopher Thomas Halsall, Laurent Francois Andre Hennequin, Alleyn Thomas Plowright, Richard Storey, Kieran Lennon
  • Quinazoline Derivatives as Antiproliferative Agents
    Publication number: 20110237610
    Abstract: The invention concerns quinazoline derivatives of Formula I wherein each of R1a, R1b, R2, R3 and a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Application
    Filed: October 12, 2010
    Publication date: September 29, 2011
    Applicant: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Laurent Francois Andre Hennequin, Christopher Thomas Halsall
  • QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
    Publication number: 20110152297
    Abstract: The invention concerns quinazoline derivatives of the Formula I, or pharmaceutically acceptable salts thereof: wherein each of R1, R2, R3, R4 and m are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, and, for example, EGFR tyrosine kinase.
    Type: Application
    Filed: February 24, 2006
    Publication date: June 23, 2011
    Inventors: Christopher Thomas Halsall, Laurent Francois Andre Hennequin, Alleyn Thomas Plowright, Richard Storey, Kieran Lennon
  • Quinazoline derivatives as antiproliferative agents
    Patent number: 7838530
    Abstract: The invention concerns quinazoline derivatives of Formula (I), wherein each of R1a, R1b, R2, R3 and a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Grant
    Filed: September 22, 2004
    Date of Patent: November 23, 2010
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Laurent Francois Andre Hennequin, Christopher Thomas Halsall
  • Compounds
    Patent number: 7709471
    Abstract: There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: May 4, 2010
    Assignee: AstraZeneca AB
    Inventors: Christopher Thomas Halsall, David Alan Rudge, Iain Simpson, Richard Andrew Ward
  • QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
    Publication number: 20090312343
    Abstract: The invention concerns quinazoline derivatives of the Formula I: wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.
    Type: Application
    Filed: June 11, 2009
    Publication date: December 17, 2009
    Inventors: Laurent Francois Andre HENNEQUIN, Christopher Thomas Halsall
  • Quinazoline compounds for the treatment of hyperproliferative disorders
    Patent number: 7632840
    Abstract: A quinazoline derivative of the formula I: wherein: R1, R2, R3, R3a, R4, R5, R5a R6, R7, a, m and p are as defined in the description. Also claimed are pharmaceutical compositions containing the quinazoline derivative, the use of the quinazoline derivatives as medicaments and processes for the preparation of the quinazoline derivative. The quinazoline derivatives of formula I, are useful in the treatment of hyperproliferative disorders such as a cancer.
    Type: Grant
    Filed: January 31, 2005
    Date of Patent: December 15, 2009
    Assignee: AstraZeneca AB
    Inventors: Benedicte Delouvrie, Craig Steven Harris, Laurent Francois Andre Hennequin, Christopher Thomas Halsall, Janet Elizabeth Pease, Peter Mark Smith
  • Quinazoline derivatives as tyrosine kinase inhibitors
    Patent number: 7569577
    Abstract: The invention concerns quinazoline derivatives of the Formula (I); wherein each of R1, R2, W, X1, X2, Z, a and b are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.
    Type: Grant
    Filed: September 13, 2004
    Date of Patent: August 4, 2009
    Assignee: Astrazeneca AB
    Inventors: Laurent Francois Andre Hennequin, Christopher Thomas Halsall
  • Quinazoline Derivatives
    Publication number: 20080234263
    Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of R1, R3, R20, X1, X2, Z, W, (a) and (q) have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of turnours which are sensitive to inhibition of erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.
    Type: Application
    Filed: September 13, 2004
    Publication date: September 25, 2008
    Inventors: Laurent Francois Andre Hennequin, Christopher Thomas Halsall
  • NOVEL COMPOUNDS
    Publication number: 20080009482
    Abstract: There is provided a compound of formula (I): processes for the manufacture thereof, pharmaceutical compositions thereof and uses in therapy.
    Type: Application
    Filed: July 5, 2007
    Publication date: January 10, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Christopher Thomas HALSALL, David Alan RUDGE, Iain SIMPSON, Richard Andrew WARD
  • 3-aminoalkyl-2-aryl-indole derivatives and their use as GnRH antagonists
    Patent number: 7256188
    Abstract: The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: August 14, 2007
    Assignee: AstraZeneca AB
    Inventors: Michael Wardleworth, Alexander Graham Dossetter, Christopher Thomas Halsall
  • Compounds
    Patent number: 6809098
    Abstract: The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: October 26, 2004
    Assignee: AstraZeneca AB
    Inventors: Michael Wardleworth, Alexander Graham Dossetter, Christopher Thomas Halsall
  • 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
    Publication number: 20040142987
    Abstract: The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds.
    Type: Application
    Filed: March 1, 2004
    Publication date: July 22, 2004
    Inventors: James Michael Wardleworth, Alexander Graham Dossetter, Christopher Thomas Halsall
  • Compounds
    Publication number: 20030171354
    Abstract: The present invention relates to compounds of formula I which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds.
    Type: Application
    Filed: August 21, 2002
    Publication date: September 11, 2003
    Applicant: AstraZeneca AB
    Inventors: Michael Wardleworth, Alexander Graham Dossetter, Christopher Thomas Halsall